05:39 AM EDT, 10/26/2026 (MT Newswires) -- Aptamer Group (APTA.L) agreed to collaborate with biotechnology company Pharmahungary Group for research into the targeted delivery of oligonucleotide therapeutics to the heart and skeletal muscle. The London-listed British synthetic binder developer said Monday it will explore a potential pharmaceutical partnership with Pharmahungary as part of the cost-sharing research collaboration. Aptamer is aiming to develop two Optimer delivery vehicles for the heart and skeletal muscle and manufacture lead conjugates using its partner's therapeutic microRNA through the collaboration.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.